Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-01-22T10:52:27.611Z Has data issue: false hasContentIssue false
  • English
  • Français

Should We Routinely Use Mupirocin to Prevent Staphylococcal Infections?

Published online by Cambridge University Press:  02 January 2015

Virginia R. Roth ,
Cathryn Murphy ,
Trish M. Perl ,
Alfred DeMaria ,
Annette H. Sohn ,
Ronda L. Sinkowitz-Cochran  and
William R. Jarvis
Virginia R. Roth*
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Atlanta, Georgia Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Public Health Service, United States Department of Health and Human Services, Atlanta, Georgia
Cathryn Murphy
Affiliation:
Department of Medicine, Johns Hopkins University, Baltimore, Maryland
Trish M. Perl
Affiliation:
Bureau of Communicable Disease Control, Massachusetts Department of Public Health, Jamaica Plain, Massachusetts
Alfred DeMaria
Affiliation:
Bureau of Communicable Disease Control, Massachusetts Department of Public Health, Jamaica Plain, Massachusetts
Annette H. Sohn
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Atlanta, Georgia
Ronda L. Sinkowitz-Cochran
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Atlanta, Georgia
William R. Jarvis
Affiliation:
Hospital Infections Program, National Center for Infectious Diseases, Atlanta, Georgia
*
Division of Infectious Diseases, The Ottawa Hospital, 501 Smyth Rd, Room G-12, Ottawa, Ontario K1H8L6, Canada
Get access Rights & Permissions [Opens in a new window]

Abstract

Routine use of mupirocin to prevent staphylococcal infections is controversial. We assessed attitudes and practices of healthcare professionals attending the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections regarding mupirocin prophylaxis. Eighty percent of participants did not use mupirocin routinely. At the end of the session, 58% indicated they would consider increased use of mupirocin.

Type
From the 4th Decennial International Conference
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 11 , November 2000 , pp. 745 - 749
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Chow, JW, Yu, VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989;149:1258–1262.Google Scholar
2.Herwaldt, LA. Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients./Hosp Infect 1998;40(suppl B):S13–S23.Google Scholar
3.Kluytmans, J, van Belkum, A, Verbrugh, H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505–520.Google Scholar
4.Bloom, BS, Fendrick, AM, Chernew, ME, Patel, P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis Patients a decision analysis. Am J Kidney Dis 1996;27:687–694.Google Scholar
5.National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance System (NNIS) System. Am J Infect Control 1996;24:380–388.Google Scholar
6.Rubin, RJ, Harrington, CA, Poon, A, Dietrich, K, Greene, JA, Moiduddin, A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:9–17.Google Scholar
7.Fridkin, SK, Gaynes, RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303–316.Google Scholar
8.Smith, TL, Pearson, ML, Wilcox, KR, Cruz, C, Lancaster, MV, Robinson-Dunn, B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. NEngl f Med 1999;340:493–501.Google Scholar
9.Sohn, AH, Sinkowitz-Cochran, RL, Jarvis, WR. Program Overview, The Reality Check Sessions at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Infect Control Hosp Epidemiol 2000;21:742–744.Google Scholar
10.Perl, TM, Golub, JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S aureus nasal carriage. Ann Pharmacother 1998;32(suppl):S7–S16.Google Scholar
11.Wenzel, RP, Perl, TM. The significance of nasal carriage oi Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13–24.Google Scholar
12.Boyce, JM. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996;17:775–779.CrossRefGoogle ScholarPubMed
13.Brown, P, Davies, DT, O'Hanlon, PJ, Wilson, JM. The chemistry of Pseudomonic acid, 15: synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. J Med Chem 1996;39:446–457.Google Scholar
14.Perl, TM, Cullen, JJ, Pfaller, MA, Wenzel, RP, Zimmerman, B, Herwaldt, LAet al. A randomized, double-blind, placebo-controlled clinical trial of intranasal mupirocin to prevent S aureus nosocomial infections. Infect Control Hosp Epidemiol 1999;20:282. Abstract 45.Google Scholar
15.Kluytmans, J. Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. J Hosp Infect 1998;40(suppl B):S25–S29.Google Scholar
16.Doebbeling, BN, Breneman, DL, Neu, HC, Aly, RYangco, BG, Holley, HP Jr, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993;17:466–474.Google Scholar
17.Boelaert, JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994;6(suppl 2):S19–S24.Google Scholar
18.Henkel, T, Finlay, J. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J Chemother 1999;11:331–337.Google Scholar
19.Miller, MA, Dascal, A, Portnoy, J, Mendelson, J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811–813.Google Scholar